“Xeljanx is expected to overcome the limitation of rheumarthritis treatments”

As the first oral treatment for rheumarthritis, Xeljanz, has been launched, it is noticed that a new era has been opened in the rheumarthritis treatment market.

Pfizer Korea announced the launch of the oral rheumarthritis treatment, ‘Xeljanz (tofacitinib citrate)’ through its press meeting on the 5^th and spoke that it expects to improve inconvenience and side effects of the existing rheumarthr...